XML 61 R46.htm IDEA: XBRL DOCUMENT v3.25.1
DISCONTINUED OPERATIONS - Additional Information (Details) - USD ($)
3 Months Ended 21 Months Ended 62 Months Ended
Apr. 24, 2024
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Apr. 23, 2024
Apr. 23, 2024
Dec. 31, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Revenue from collaborative agreement   $ 0   $ 973,000      
Accounts receivable   1,694,000         $ 1,694,000
Total revenues | Rezafungin              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Liabilities related to discontinued operations   0         0
Assets related to discontinued operations   0         0
Cash provided by (used in) operating activities, discontinued operations       6,900,000      
Cash provided by (used in) financing activities, discontinued operations   0   0      
Cash provided by (used in) investing activities, discontinued operations   0   0      
Total revenues       7,490,000      
Total revenues | Rezafungin | Related Party | Collaborative Arrangement              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Revenue, remaining performance obligation, amount   0          
Accounts receivable   0         $ 0
Napp Pharmaceutical Group Limited | Total revenues | Rezafungin | Related Party | Collaborative Arrangement              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Collaborative agreement, maximum cost share, forgiveness amount $ 11,100,000            
Collaborative arrangement, carry over services agreement term (in days) 45 days            
Collaborative arrangement, other services agreement term (in days) 75 days            
Collaborative arrangement, transaction, value $ 21,200,000            
Contract liabilities, forgiveness amount 25,300,000            
Transition services 600,000            
Payments related to collaborative agreement 2,100,000            
Accounts receivable, forgiveness amount 2,600,000            
Total revenues     $ 100,000        
Loss on disposal of discontinued operations $ 300,000            
Collaborative arrangement, transitions services term (in days) 76 days            
Revenue, remaining performance obligation, amount   0          
Accounts receivable   $ 1,700,000          
Napp Pharmaceutical Group Limited | Total revenues | Rezafungin | Related Party | Collaborative Arrangement | Rezafungin Assets              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Total revenues $ 20,800,000            
Melinta | Total revenues | Rezafungin | Related Party | Collaborative Arrangement              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Payments related to collaborative agreement         $ 30,000,000    
Revenue from collaborative agreement       393,000      
Melinta | Total revenues | Rezafungin | Related Party | Collaborative Arrangement | Milestone Achievement              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Revenue from collaborative agreement         $ 20,000,000    
Mundipharma | Total revenues | Rezafungin | Related Party | Collaborative Arrangement              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Payments related to collaborative agreement           $ 30,000,000  
Collaborative agreement, maximum cost share           31,200,000  
Revenue from collaborative agreement       $ 7,097,000      
Mundipharma | Total revenues | Rezafungin | Related Party | Collaborative Arrangement | Milestone Achievement              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Revenue from collaborative agreement           $ 27,900,000